[Inclusion Criteria]

          -  Provision of informed consent prior to any study specific procedures

          -  Men and women aged at least 18 years

          -  Small cell lung cancer harboring RICTOR amplification

          -  Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no
             deterioration over the previous 2 weeks

          -  Minimum life expectancy of 12 weeks

          -  Patients must have acceptable bone marrow, liver and renal function measured within 14
             days prior to administration of study treatment as defined below:

          -  At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and follow up visits.

          -  No history of non-autologous bone marrow transplant.

        Exclusion Criteria:

          -  Participation in another clinical study with an investigational product during the
             last 21 days.

          -  Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide,
             immunotherapy, other anticancer agents within 21 days of starting study treatment.
             Prior use of an investigational monoclonal antibody therapy within 3 months.

          -  Major surgery within 4 weeks prior to study entry (excluding placement of vascular
             access), or minor surgery (excluding tumour biopsies) within 14 days of first dose of
             study treatment.

          -  Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP
             if taken within the stated washout periods before the first dose of study treatment
             (see Appendix 1)

          -  Exposure to specific substrates of the drug transporters OATP1B1, OATP1B3, MATE1 and
             MATE2K within the appropriate wash-out period

          -  Any haemopoietic growth factors within 14 days prior to receiving study treatment.

          -  Pre-treatment with other PI3K, AKT, dual PI3K/mTRO and mTOR inhibitors

          -  Spinal cord compression and/or brain metastases unless asymptomatic or treated and
             stable off steroids for at least 4 weeks prior to start of study treatment.